India Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The india diabetes devices market size is estimated at USD 2.67 billion in 2026, and is expected to reach USD 3.02 billion by 2031, at a CAGR of 2.49% during the forecast period (2026-2031). This report is Segmented by Product Type (Monitoring Devices, Management Devices), Patient Type (Type-1 Diabetes, Type-2 Diabetes), and End User (Hospitals & Specialty Clinics, Primary Care & Diabetes Centres, Home-Care Settings). The Market Forecasts are Provided in Terms of Value (USD).

India Diabetes Devices Market Trends and Insights

Rising Prevalence of Obesity Among Youth Accelerating Earlier-Onset Diabetes

India’s adolescent obesity wave is pulling diabetes incidence into the under-35 cohort, creating multi-decade device demand. A 2024 Journal of the Endocrine Society study reported 17.9% diabetes prevalence among Indians below 35 years. Device makers are repositioning: Dexcom launched ONE+ in 2024 at INR 4,000 per month, promoting smartphone-linked insights for young Type 2 users. Employer wellness plans follow suit, with MediBuddy data showing 24.40% pre-diabetes prevalence in employees aged 18-45, prompting group policies that bundle CGM rentals. Convergence of dyslipidemia and hypertension in obese youth strengthens the business case for integrated CGM platforms over stand-alone glucometers. The India diabetes devices market increasingly orients product roadmaps around this technology-savvy demographic.

Expanding Public Reimbursement for CGM Sensors

The Central Government Health Scheme raised the ceiling to INR 300,000 for sensor-augmented pumps and INR 4,000 for 14-day CGM use in its 2024 rate list. Although only 4 million beneficiaries currently qualify, the policy shift signals strategic support for continuous monitoring. Tamil Nadu’s state plan added annual CGM coverage for Type-1 patients, capping benefits at INR 50,000. Limited physician familiarity stalls uptake: the Indian Diabetes Federation found fewer than 30% of primary-care doctors were trained to interpret ambulatory glucose profiles. Still, the reimbursement tailwind is material to the India diabetes devices market trajectory as other states emulate early adopters.

High Out-of-Pocket Costs on Testing Consumables

SMBG strips cost INR 380-1,993 per pack, implying an annual spend of INR 13,860-19,930 for twice-daily testing. Abbott’s FreeStyle Libre 3 sensor at INR 5,000 every 14 days lifts annual CGM spend to INR 130,000. These figures exceed the median household income in many tier-3 cities, forcing patients to ration tests and slowing the transition to CGM. Private insurers cap diabetes consumable reimbursement at around INR 10,000 per year, covering less than 10% of CGM expenses. Affordability remains the sharpest brake on the India diabetes devices market.

Other drivers and restraints analyzed in the detailed report include:

• Rising Prevalence and Earlier Onset of Type-2 Diabetes
• Government PLI Scheme Spurring Local Diabetes-Device Manufacturing
• Low CGM-Prescription Awareness Among Primary-Care Physicians

Segment Analysis

Management devices are forecast to post a 3.53% CAGR through 2031, outstripping monitoring counterparts. Demand rides on rapid insulin-pump uptake among 1.2 million Type-1 patients and swelling disposable-pen use in urban Type-2 cohorts. Medtronic’s MiniMed 780G hybrid closed-loop system, launched in 2024, automatically adjusts basal insulin every five minutes and has widened time-in-range by 15% in Indian trials. AgVa Healthcare’s INSUL pump, locally priced at INR 24,999, undercuts imported pumps by 90% and integrates Bluetooth dosing logs, capturing value-conscious consumers. Schott’s domestic cartridge tubing reduced landed costs on insulin pens by 20%, encouraging Novo Nordisk to phase out vial formats in favor of FlexPen devices.

Monitoring devices still delivered a 61.78% revenue share in 2025, buoyed by 80 million glucometer users; however, their 1.9% CAGR lags behind the market pace. SMBG strips remain the default for price-sensitive buyers, but CGM is the fastest-growing sub-segment. Abbott’s Libre 3 sensor measures just 2.9 mm in diameter and beams one-minute readings via Bluetooth, while Dexcom’s ONE+ offers a 10-day sensor life at INR 4,000 per month. Combined, these launches have nudged the India diabetes devices market toward continuous data capture, although premium pricing keeps penetration below 7% of diagnosed diabetics.

Complete Report Scope:

• By Product Type
  • Monitoring Devices
    • Self-Monitoring Blood Glucose Devices
    • Continuous Glucose Monitoring
  • Management Devices
    • Insulin Pumps
    • Insulin Syringes
    • Insulin Cartridges
    • Disposable Pens
    • Other Management Devices
• By Patient Type
  • Type-1 Diabetes
  • Type-2 Diabetes
• By End User
  • Hospitals & Specialty Clinics
  • Primary Care & Diabetes Centres
  • Home-Care Settings

List of Companies Covered in this Report:

• Abbott Laboratories
• AgVa Healthcare
• Ascensia
• Becton Dickinson (BD)
• Beckton Dickinson
• Dexcom
• Eli Lilly and Company
• HTL-Strefa
• Insulet
• LifeScan (J&J)
• Medtronic
• Nipro
• Novo Nordisk
• Roche
• Sanofi
• Senseonics
• Tandem Diabetes Care
• Terumo
• Ypsomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support